Skip to content

Author

Jianchun Duan

1 paper indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Review Aug 2026

Sutetinib for Patients with Non-Small Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Multicenter, Open-Label, Phase IIb Trial.

Findings support sutetinib as a potential treatment option for this molecularly heterogeneous population of adults with locally advanced or metastatic NSCLC harboring uncommon EGFR mutations and demonstrate clinically meaningful antitumor activity with a manageable safety profile.

Feng-Ying Wu, Wei Zhang, Yan-Qiu Zhao et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.